The Trial of SHR6508 in Secondary Hyperparathyroidism

NCT06434961 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: SHR6508 plus oral placebo tablets
DRUG: Cinacalcet plus intravenous placebo

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.